ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AD-118

A development code. Also written as “AD-118, AD-1181”.

Its studies are mostly in Heart Failure, led by Yuhan.

Furthest: phase 1, since Mar 12, 20262 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Yuhan22 open or runningphase 1since Mar 12, 2026Mar 12, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2026First study: phase 1 study in Chronic Heart FailureFirst studyNCT07476157 · 70 planned · South Korea
  2. Jul 16, 2026Phase 1 study in Chronic Heart FailureNCT07717749 · 74 planned · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07717749Chronic Heart Failure · South Korea1Not yet recruitingAug 202674
NCT07476157Chronic Heart Failure · South Korea1Not yet recruitingMay 202670

How it is read

Names in the registry

  • “AD-118, AD-1181”, 3 entries

Codes read as this program: AD118.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.